高特佳投资副总经理于建林：锚定下一代疗法 创新药行业走向价值深化

Group 1 - The core viewpoint of the articles highlights the rapid growth and high-quality development of China's innovative pharmaceutical industry, with 69 innovative drugs approved in 2025, surpassing the previous year's total of 48, marking a historical high [1] - China's pharmaceutical industry is now the second largest globally, with approximately 30% of the world's innovative drugs in development [1] - The industry is expected to maintain high-speed growth through 2026, with increased R&D investment and a shift towards profitability for more companies, particularly in key areas like ADC, bispecific antibodies, and CGT [1] Group 2 - In 2025, the value of business development (BD) transactions in China's innovative drug sector is projected to exceed $100 billion, indicating a shift from mere scale expansion to value enhancement [2] - China has become the largest source of licensing globally, with 90% of the top 20 multinational pharmaceutical companies collaborating with Chinese innovative drug pipelines [2] - However, the proportion of first-in-class (FIC) drugs remains low, and most BD activities are still concentrated in early-stage licensing, which limits potential future revenues [2][3] Group 3 - The current low pricing of Chinese biotech assets in overseas transactions is attributed to several factors, including the predominance of early-stage licensing and the need for additional validation of clinical data [4] - The Co-Co model, which involves shared development costs, is not expected to become mainstream in the short term due to the financial pressures on companies, although it is gaining traction among leading firms [5] Group 4 - The Hong Kong stock market remains a key listing venue for unprofitable biotech companies, with IPO financing in the healthcare sector leading globally and over 60% of shares held by international institutional investors [6] - The valuation focus for Hong Kong-listed innovative drug companies is shifting towards BD capabilities, clinical progress, and global commercialization potential [8] Group 5 - Future investment trends in China's innovative drug sector are expected to emphasize high technical barriers and commercialization potential, with a move away from follow-on innovation projects [12] - The BD capabilities will become a core valuation anchor, with transaction models evolving from single rights buyouts to more collaborative approaches [12]